A5071951498- COVID-19 Clinical Research Studies
- Long-Term Effects of COVID-19
- SARS-CoV-2 and COVID-19 Research
- COVID-19 and Mental Health
- Respiratory Support and Mechanisms
- COVID-19 and healthcare impacts
- Intensive Care Unit Cognitive Disorders
- HIV/AIDS Research and Interventions
- HIV/AIDS drug development and treatment
- COVID-19 Impact on Reproduction
- HIV-related health complications and treatments
- Facial Rejuvenation and Surgery Techniques
- Maternal Mental Health During Pregnancy and Postpartum
- Pneumocystis jirovecii pneumonia detection and treatment
- HIV Research and Treatment
- Vaccine Coverage and Hesitancy
- Inflammasome and immune disorders
- Sepsis Diagnosis and Treatment
- Hair Growth and Disorders
- Tuberculosis Research and Epidemiology
- Atherosclerosis and Cardiovascular Diseases
- Mental Health and Patient Involvement
- COVID-19 diagnosis using AI
- Facial Nerve Paralysis Treatment and Research
- Immune responses and vaccinations
Oslo University Hospital
2006-2024
Johns Hopkins Hospital
2024
All India Institute of Medical Sciences Rishikesh
2023
All India Institute of Medical Sciences Raipur
2023
Weatherford College
2007
Significance The new SARS-CoV-2 pandemic leads to COVID-19 with respiratory failure, substantial morbidity, and significant mortality. Overactivation of the innate immune response is postulated trigger this detrimental process. complement system a key player in immunity. Despite few reports local activation, there lack evidence that degree systemic activation occurs early patients, whether associated failure. This study shows number products are systemically, consistently, long-lastingly...
Abstract In SARS-CoV-2 infection there is an urgent need to identify patients that will progress severe COVID-19 and may benefit from targeted treatment. this study we analyzed plasma cytokines in investigated their association with respiratory failure (RF) treatment Intensive Care Unit (ICU). Hospitalized (n = 34) confirmed were recruited into a prospective cohort study. Clinical data blood samples collected at inclusion after 2–5 7–10 days. RF was defined as PaO2/FiO2 ratio (P/F) < 40...
Abstract Background Baricitinib has shown efficacy in hospitalized patients with COVID-19, but no placebo-controlled trials have focused specifically on severe/critical COVID, including vaccinated participants. Methods Bari-SolidAct is a phase-3, multicentre, randomised, double-blind, trial, enrolling participants from June 3, 2021 to March 7, 2022, stopped prematurely for external evidence. Patients COVID-19 were randomised 4 mg once daily or placebo, added standard of care. The primary...
Abstract Background Immune dysregulation is a major factor in the development of severe coronavirus disease 2019 (COVID-19). The homeostatic chemokines CCL19 and CCL21 have been implicated as mediators tissue inflammation, but data on their regulation acute respiratory syndrome 2 (SARS-CoV-2) infection limited. We thus investigated levels these COVID-19 patients. Methods Serial blood samples were obtained from patients hospitalized with (n = 414). Circulating during hospitalization 3-month...
The current study examined the efficacy of a web-based intervention (WBI; Avanti) on symptoms depression and well-being for patients diagnosed with HIV. A two-armed randomized trial recruited antiretroviral therapy (ART) at an outpatient clinic. Thirty-six were allocated to Avanti 31 control group. Primary outcomes subjective (SWB), secondary included life satisfaction affect balance. Paired tests showed that only following had significant improvements in SWB by 3 months as well No...
Objectives Facial lipoatrophy can be devastating for HIV‐infected patients, with negative effects on self‐esteem. In this study, we treated facial fat atrophy in the nasogenian area hyaluronic acid (Restylane SubQ; Q‐Med AB, Uppsala, Sweden). Methods Twenty patients were included study. Treatment evaluated at baseline, and weeks 6, 24 52 using ultrasound, Global Aesthetic Improvement Scale, Visual Analogue Scale Rosenberg Self‐Esteem Scale. Results Mean (±standard deviation) total cutaneous...
Facial lipoatrophy can be a stigmatizing side effect of antiretroviral (AVR) treatment for HIV-infected patients. We sought to evaluate the long-term efficacy and safety new formulation hyaluronic acid that injected in larger amounts into deeper skin layers during 3 years follow-up.Twenty patients received injections Restylane SubQ(). Refill was offered at 12 24 months. Treatment effects were evaluated using ultrasound, Global Aesthetic Improvement Scale, visual analogue scale (VAS)...
Antiretroviral treatment (ART) has converted HIV from a lethal disease to chronic condition, yet co-morbidities persist. Incomplete immune recovery and activation, especially in the gut mucosa, contribute these complications. Inflammasomes, multi-protein complexes activated by innate receptors, appear play role inflammatory responses. In particular, preliminary data indicate involvement of IFI16 NLRP3 inflammasomes infection. This study explores inflammasome function monocytes people with...
Abstract Background: In SARS-CoV-2 infection there is an urgent need to identify patients that will progress severe COVID-19 and may benefit from targeted treatment. Objectives: Analyze plasma cytokines in investigate their association with respiratory failure (RF) treatment Intensive Care Unit (ICU). Method: Hospitalized (n=34) confirmed were recruited into a prospective cohort study. Clinical data blood samples collected at inclusion after 2-5 7-10 days. RF was defined as PaO2/FiO2 ratio...
Efavirenz is dosed once daily, and generally administered in the evening owing to its central nervous system side-effects. This study assessed tolerability of switching morning dosing efavirenz. Of 49 patients included, 24 chose continue dosing. Morning efavirenz may result fewer side-effects improved adherence for some patients.
In Norway, treatment with COVID-19 convalescent plasma has been given through the NORPLASMA project. The was initially offered to critically ill patients after an individual assessment, but from December 2020, indication limited ill, immunocompromised patients. this article we describe clinical characteristics, comorbidity and mortality in who received these two periods.From 22 April 2020 30 March 2022, a total of 79 were included observational studies MONITOR Norwegian SARS-CoV-2 study. had...
The COVID-19 pandemic posed a challenge for people living with HIV (PLWH), particularly immune non-responders (INR) compromised CD4 T-cell reconstitution following antiretroviral therapy (CD4 count <350 cells per mm
Background: Respiratory failure in the ongoing SARS-CoV-2 pandemic is hypothesised to be driven by an over-reacting innate immune response The complement syste
Purpose of the study One most prevalent mental conditions in people with HIV is depression as uniquely characterized by low positive affect. This examined effect a web‐based intervention (Avanti) on overall mood and depressive symptoms among patients infection. Methods Patients treated effective antiretroviral treatment were included two‐armed trial substance abuse an exclusion criterion randomized to Avanti (n=36) or control (n=31). surveyed at baseline, well 1 3 months after initiation...
Purpose of the study Due to a pharmacokinetic interaction leading reduced serum levels atazanavir (ATV) when combined with tenofovir (TDF), it is recommended add ritonavir (r) as booster for TDF. However, ATV also licensed use an unboosted drug. In our clinic many patients switched after viral suppression was achieved, mostly simplification. We report on efficacy TDF and emtricitabine (FTC) in cohort. Methods File review all no history virological failure commencing (400 mg)+TDF+FTC...
7‐11 November 2010, Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK